Evidence map›Paper›PMID 35124410›Full record

ArticleLung cancer (Amsterdam, Netherlands)2022

Procedural complications associated with invasive diagnostic procedures after lung cancer screening with low-dose computed tomography.

Shuang Yang, Ya-Chen Tina Shih, Jinhai Huo, Hiren J Mehta, Yonghui Wu, Ramzi G Salloum, Michelle Alvarado, Dongyu Zhang, Dejana Braithwaite, Yi Guo and 1 more

Open access · greenAbstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shuang YangDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States.
Ya-Chen Tina ShihDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jinhai HuoBristol-Myers Squibb, Princeton Pike, NJ, United States.
Hiren J MehtaDivision of Pulmonary, Critical Care, and Sleep Medicine, College of Medicine, University of Florida, Gainesville, FL, United States.
Yonghui WuDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States.
Ramzi G SalloumDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States.
Michelle AlvaradoDepartment of Industrial and Systems Engineering, University of Florida, Gainesville, FL, United States.
Dongyu ZhangCancer Control and Population Sciences Program, University of Florida, Gainesville, FL, United States.
Dejana BraithwaiteCancer Control and Population Sciences Program, University of Florida, Gainesville, FL, United States.
Yi GuoDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: yiguo@ufl.edu.
Jiang BianDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: bianjiang@ufl.edu.
University of Florida · USThe University of Texas MD Anderson Cancer Center · US

Funding

The benefits and harms of lung cancer screening in FloridaR01CA246418 · NCI · UNIVERSITY OF FLORIDA · PI BIAN, JIANG, GUO, YI · 2020 to 2023
$1.7M
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in FloridaU18DP006512 · DP · UNIVERSITY OF FLORIDA · PI BIAN, JIANG, GUO, YI · 2020 to 2024
$1.4M
Using Electronic Health Records from a Large Clinical Data Research Network to Understand Cancer Burden and Cancer Risks Among Transgender and Gender Nonconforming (TGNC) IndividualsR21CA245858 · NCI · UNIVERSITY OF FLORIDA · PI BIAN, JIANG, GUO, YI · 2020 to 2021
$773k
Optimizing the Population Representativeness of Older Adults in Alzheimer's Disease and Related Dementia Clinical TrialsR21AG068717 · NIA · UNIVERSITY OF FLORIDA · PI BIAN, JIANG, GUO, YI · 2020 to 2021
$419k
Optimizing the Population Representativeness of Older Adults in Cancer TrialsR21CA253394 · NCI · UNIVERSITY OF FLORIDA · PI BIAN, JIANG, GUO, YI · 2021 to 2021
$392k
NCCDPHP CDC HHS U18 DP006512NCI NIH HHS R01 CA246418NCI NIH HHS R21 CA245858NCI NIH HHS R21 CA253394NIA NIH HHS R21 AG068717
6 · The paper itself

Abstract

introductionAlthough the National Lung Screening Trial (NLST) has proven low-dose computed tomography (LDCT) is effective for lung cancer screening, little is known about complication rates from invasive diagnostic procedures (IDPs) after LDCT in real-world settings. In this study, we used the real-world data from a large clinical research network to estimate the complication rates associated with IDPs after LDCT.

methodsUsing 2014-2021 electronic health records and claims data from the OneFlorida clinical research network, we identified case individuals who underwent an IDP (i.e., cytology or needle biopsy, bronchoscopy, thoracic surgery, and other surgery) within 12 months of their first LDCT. We matched each case with one control individual who underwent an LDCT but without any IDPs. We calculated 3-month incremental complication rates as the difference in the complication rate between the case and control groups by IDP and complication severity.

resultsAmong 7,041 individuals who underwent an LDCT, 301 (4.3%) subsequently had an IDP within 12 months following the LDCT. The overall 3-month incremental complication rate was 16.6% (95% confidence interval [CI]: 9.9% - 23.1%), higher than that reported in the NLST (9.4%). The overall incremental complication rate was 5.6% (95% CI: 1.9% - 9.6%) for major, 8.6% (95% CI: 3.1% - 14.1%) for intermediate, and 13.2% (95% CI: 8.1% - 18.5%) for minor complications.

conclusionsIt is important to ensure adherence to clinical guidelines for nodule management and downstream work-up to minimize potential harms from screening.

Indexed as

ClaimsClinical research networkElectronic health recordsReal-world data

Identifiers

PMID35124410
PMCPMC9250944
OpenAlexW4205318730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.